KDR and non-small cell lung carcinoma: For instance, in non-small-cell lung cancer (NSCLC) xenograft models, nintedanib concurrently inhibits VEGFR and FGFR activities, significantly reduces tumor angiogenesis, and, when combined with immunotherapy, promotes CD8+ T cell infiltration, thereby augmenting antitumor immune responses [126,127,128].